Found: 8
Select item for more details and to access through your institution.
Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.
- Published in:
- Oncogene, 2012, v. 31, n. 3, p. 269, doi. 10.1038/onc.2011.245
- By:
- Publication type:
- Article
Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.
- Published in:
- Oncogene, 2010, v. 29, n. 41, p. 5630, doi. 10.1038/onc.2010.301
- By:
- Publication type:
- Article
Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.
- Published in:
- Oncogene, 2009, v. 28, n. 37, p. 3296, doi. 10.1038/onc.2009.184
- By:
- Publication type:
- Article
BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
- Published in:
- Oncogene, 2008, v. 27, n. 15, p. 2237, doi. 10.1038/sj.onc.1210852
- By:
- Publication type:
- Article
Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.
- Published in:
- Oncogene, 2003, v. 22, n. 15, p. 2334
- By:
- Publication type:
- Article
Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors.
- Published in:
- 2001
- By:
- Publication type:
- journal article
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 322, doi. 10.1002/hon.132_2630
- By:
- Publication type:
- Article
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 322, doi. 10.1002/hon.132_2630
- By:
- Publication type:
- Article